- Title
- TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer
- Creators
- Ritu SalaniKristina LindemannZhongqiu LinShin NishioAna OakninJean-Emmanuel KurtzGiorgio ValabregaM. Valeria CáceresPhilipp HarterLucy GilbertAzmat H. SadozyeLilian Arruda Do Rêgo BarrosToon Van GorpIngrid BoereChristian MarthLinda DuskaBradley J. MonkXin Tong LiCumhur TekinMansoor Raza Mirza
- Publication Details
- International journal of gynecological cancer, Vol.35(2), p.100497
- Identifiers
- 991006146789902656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer
International journal of gynecological cancer, Vol.35(2), p.100497
02/2025
Metrics
1 Record Views